Related Experiment Video
Updated: Aug 5, 2026
11:36
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Azulfidine- (sulfasalazine-) induced hepatic injury
The American Journal of Digestive Diseases
|October 1, 1978
Summary
A patient experienced Azulfidine-induced liver damage, with symptoms recurring upon re-exposure. This case highlights an acquired hypersensitivity reaction to Azulfidine, emphasizing the need for careful monitoring.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Immunology
Background:
- Hepatotoxicity is a potential adverse effect of certain medications.
- Sulfasalazine (Azulfidine) is used to treat inflammatory conditions.
- Drug-induced liver injury can manifest in various ways.
Purpose of the Study:
- To report a case of Azulfidine-related hepatotoxicity.
- To investigate the mechanism of liver injury associated with Azulfidine.
- To highlight the potential for hypersensitivity reactions to Azulfidine.
Main Methods:
- Case report detailing clinical presentation and laboratory findings.
- Observation of symptom recurrence upon drug re-administration.
- Assessment of clinical and biochemical features to determine reaction type.
Main Results:
- The patient presented with fever, skin rash, and hepatocellular injury.
- Symptoms and laboratory abnormalities recurred promptly after Azulfidine re-challenge.
- The pattern of recurrence strongly suggested an acquired hypersensitivity.
Conclusions:
- This case illustrates Azulfidine-induced hepatotoxicity.
- The findings support an acquired hypersensitivity reaction as the cause.
- Clinicians should be aware of potential hypersensitivity to Azulfidine.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...